Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019

October 16, 2019 — Researchers have shown for the first time in preclinical studies that the...

Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019

September 30, 2019 – Data from the EVOLVE Short DAPT study found that shortened three-month...

Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019

September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed...

FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019

September 18, 2019 — AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track...

PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019

September 11, 2019 — The angiotensin...

Prasugrel Cuts Ischemic Events in Acute Coronary Syndrome Patients
News | Antiplatelet and Anticoagulation Therapies | September 09, 2019

September 9, 2019 — Prasugrel is superior to ticagrelor for reducing ischemic events in patients with acute coronary...

Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019

September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF...

Overlay Init